BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23621229)

  • 1. Survival of mesothelioma in a palliative medical care unit in egypt.
    Ibrahim N; Abou-Elela E; Darwish D
    Asian Pac J Cancer Prev; 2013; 14(2):739-42. PubMed ID: 23621229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
    Zauderer MG; Kass SL; Woo K; Sima CS; Ginsberg MS; Krug LM
    Lung Cancer; 2014 Jun; 84(3):271-4. PubMed ID: 24690410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERCC1 as a biological marker guiding management in malignant pleural mesothelioma.
    Cihan YB; Ozturk A; Arslan A; Deniz K; Baran M; Karaca H
    Asian Pac J Cancer Prev; 2014; 15(10):4117-23. PubMed ID: 24935356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma.
    Maruyama R; Shoji F; Okamoto T; Miyamoto T; Miyake T; Nakamura T; Ikeda J; Aoki Y; Wataya H; Asoh H; Ichinose Y
    Jpn J Clin Oncol; 2005 Aug; 35(8):433-8. PubMed ID: 16006571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
    Mutlu H; Buyukcelik A; Karaca H; Aksahin A; Berk V; Aslan T; Erden A; Akca Z; Ozkan M
    Asian Pac J Cancer Prev; 2013; 14(6):3887-9. PubMed ID: 23886202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
    Habib EE; Fahmy ES
    Clin Transl Oncol; 2013 Nov; 15(11):965-8. PubMed ID: 23408040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
    Toyokawa G; Takenoyama M; Hirai F; Toyozawa R; Inamasu E; Kojo M; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Shimokawa M; Seto T; Ichinose Y
    Int J Clin Oncol; 2014 Aug; 19(4):601-6. PubMed ID: 24158772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
    de Perrot M; Feld R; Cho BC; Bezjak A; Anraku M; Burkes R; Roberts H; Tsao MS; Leighl N; Keshavjee S; Johnston MR
    J Clin Oncol; 2009 Mar; 27(9):1413-8. PubMed ID: 19224855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey.
    Kucukoner M; Ali Kaplan M; Inal A; Urakci Z; Abakay O; Cetin Tanrikulu A; Abakay A; Selim Sen H; Turkcu G; Senyigit A; Buyukbayram H; Isikdogan A
    J BUON; 2014; 19(1):164-70. PubMed ID: 24659659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA; Ceresoli GL; Garassino I; De Vincenzo F; Cavina R; Campagnoli E; Cappuzzo F; Salamina S; Soto Parra HJ; Santoro A
    Cancer; 2008 Apr; 112(7):1555-61. PubMed ID: 18286536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases.
    Metaxas Y; Cathomas R; Mark M; von Moos R
    Lung Cancer; 2016 Dec; 102():136-138. PubMed ID: 27440191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens.
    Mujoomdar AA; Tilleman TR; Richards WG; Bueno R; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):352-5. PubMed ID: 20653100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
    Shukuya T; Takahashi T; Imai H; Tokito T; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Yamamoto N
    Respir Investig; 2014 Mar; 52(2):101-6. PubMed ID: 24636265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma.
    de Lima VA; Sørensen JB
    Med Oncol; 2015 Feb; 32(2):458. PubMed ID: 25572813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA; Perrino M; Lorenzi E; Ceresoli GL; De Vincenzo F; Simonelli M; Gianoncelli L; De Sanctis R; Giordano L; Santoro A
    Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
    Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
    Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.
    de Gooijer CJ; van der Noort V; Stigt JA; Baas P; Biesma B; Cornelissen R; van Walree N; van Heemst RC; Soud MY; Groen HJM; den Brekel AJS; Buikhuisen WA; Bootsma GP; Dammeijer F; van Tinteren H; Lalezari F; Aerts JG; Burgers JA;
    Lancet Respir Med; 2021 Jun; 9(6):585-592. PubMed ID: 33515500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
    Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
    Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy.
    Takuwa T; Hashimoto M; Matsumoto S; Kondo N; Kuribayash K; Nakano T; Hasegawa S
    Int J Clin Oncol; 2017 Oct; 22(5):857-864. PubMed ID: 28439676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.